Skip to main content
Premium Trial:

Request an Annual Quote

Phenomix Inks Deal with Genentech

NEW YORK, July 12 (GenomeWeb News) - Phenomix said today that it has signed a deal to help Genentech identify and prioritize drug targets for the treatment of immune disorders.

 

Under the terms of the multi-year deal, Phenomix will use its forward genetics technology to identify new disease targets in immunology. Genentech will have the exclusive global rights to develop therapeutics using the targets, while Phenomix retains the rights to develop undisclosed products based on certain targets.

 

Phenomix said it will receive an upfront fee and an equity investment from Genentech, as well as research funding and milestones. Additional terms were not disclosed.

 

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.